Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia

Acta Haematologica

Volumn 127, Issue 1, 2011, Pages 47-49

  Xiao, Xiang ^a   Zhang, Yang ^a   Zhang, Guang Sen ^a   Zheng, Wen Li ^a   Xiao, Le ^a   Liu, Su Fang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; BCR ABL PROTEIN; BCR ABL1 PROTEIN; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE 2V617F; THALIDOMIDE; UNCLASSIFIED DRUG;

ACUTE DIARRHEA; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER DIAGNOSIS; CANCER PATIENT; CASE REPORT; CHINESE MEDICINE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC TRANSCRIPTION; HERBAL MEDICINE; HUMAN; LABORATORY TEST; LUNG INFECTION; LUNG INSUFFICIENCY; MALE; MYELOFIBROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOCYTHEMIA;

AGED; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION, MISSENSE; RNA, MESSENGER; RNA, NEOPLASM;

EID: 80054830542     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000331564     Document Type: Article

References (7)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
2. Mizutani S, Kuroda J, Shimizu D, Horiike S, Taniwaki M: Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia. Int J Hematol 2010; 91: 516-521.
3. Pingali SR, Mathiason MA, Lovrich SD, Go RS: Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 2009; 9:E25-E29.
4. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, Wooster R, Stratton MR, Futreal PA, Green AR: The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920-2921.
5. Bornhäuser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G, Thiede C: Concurrent JAK2(V617F) mutation and Bcr/Abl translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21: 1824-1826.
6. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina M, Bosi A, Francesco L: Insights into JAK2- V617F mutation in CML. Lancet Oncol 2007; 8: 864-866.
7. Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Laï JL, Rose C, Preudhomme C: JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008; 22: 1454-1455.